Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Pipeline Review, H1 2016

  • ID: 3753821
  • Report
  • 46 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Angelini Group
  • Calico LLC
  • FORMA Therapeutics, Inc.
  • Genentech, Inc.
  • OncoTartis, Inc.
  • MORE
Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Pipeline Review, H1 2016

Summary

‘Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Pipeline Review, H1 2016’, provides in depth analysis on Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) targeted pipeline therapeutics.

The report provides comprehensive information on the Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12)
- The report reviews Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) targeted therapeutics and enlists all their major and minor projects
- The report assesses Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Angelini Group
  • Calico LLC
  • FORMA Therapeutics, Inc.
  • Genentech, Inc.
  • OncoTartis, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) Overview

Therapeutics Development

Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Products under Development by Stage of Development

Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Products under Development by Therapy Area

Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Products under Development by Indication

Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Pipeline Products Glance

Early Stage Products

Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Products under Development by Companies

Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Products under Development by Universities/Institutes

Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Companies Involved in Therapeutics Development

Angelini Group

Aurigene Discovery Technologies Limited

Calico LLC

FORMA Therapeutics, Inc.

Genentech, Inc.

Karyopharm Therapeutics, Inc.

OncoTartis, Inc.

Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Drug Profiles

AU-4869 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Inhibit NAMPT for Inflammation and Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GNE-617 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KPT-9274 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OT-82 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P- BEFizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P7-C3A20 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate NAMPT for Neurological Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit NAMPT for Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit NAMPT for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STF-118804 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Dormant Projects

Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Discontinued Products

Nicotinamide Phosphoribosyl Transferase (NAmPRTase or Pre-B-Cell Colony-Enhancing Factor 1 or EC 2.4.2.12) - Featured News & Press Releases

Mar 16, 2016: Karyopharm to Present Data on Oncology drug KPT-9274 at the 2016 American Association for Cancer Research Annual Meeting

Apr 18, 2015: Aurigene to Present its NAMPT Inhibitors Programs at AACR 2015

Nov 01, 2013: Novel drug discovery method designed by Stanford scientists

Apr 02, 2013: Aurigene To Present Poster On NAMPT Inhibitor Program At AACR 2013

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Angelini Group, H1 2016

Pipeline by Aurigene Discovery Technologies Limited, H1 2016

Pipeline by Calico LLC, H1 2016

Pipeline by FORMA Therapeutics, Inc., H1 2016

Pipeline by Genentech, Inc., H1 2016

Pipeline by Karyopharm Therapeutics, Inc., H1 2016

Pipeline by OncoTartis, Inc., H1 2016

Dormant Projects, H1 2016

Discontinued Products, H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Angelini Group
Aurigene Discovery Technologies Limited
Calico LLC
FORMA Therapeutics, Inc.
Genentech, Inc.
Karyopharm Therapeutics, Inc.
OncoTartis, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll